Evaluation of HVEM and PD-L1 Expression Profile in Tumors as Potential Predictive Biomarkers forHFB200603, a BTLA antagonist, as Monotherapy and in Combination with Tislelizumab

Evaluation of HVEM and PD-L1 Expression Profile in Tumors as Potential Predictive Biomarkers forHFB200603, a BTLA antagonist, as Monotherapy and in Combination with Tislelizumab